# Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

> **NCT04551898** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 181 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** BGB-DXP593
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04551898
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-02
- **Primary completion:** 2021-05-25
- **Final completion:** 2021-05-25
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551898, "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04551898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*